Rituximab in stem cell transplantation (SCT).
| Rituximab . | Purpose . |
|---|---|
| Abbreviations: DLI, donor lymphocyte infusion; EBV, Epstein-Barr virus; GVHD, graft-versus-host disease; GVL, graft-versus-lymphoma; MRD, minimal residual disease | |
| Cytoreduction for relapsed disease | Attain a state of minimal disease before SCT |
| In autologous SCT | |
| During stem cell harvest | In vivo purge |
| Maintenance after SCT | Treat MRD |
| In allogeneic SCT | |
| With conditioning regimen | Enhance GVL and tumor kill, decrease risk of GVHD |
| With DLI | Treat MRD, enhance GVL |
| Post-transplantation complications | |
| Chronic GVHD | Treat manifestations |
| EBV-associated lymphoma | Treat and prevent |
| Rituximab . | Purpose . |
|---|---|
| Abbreviations: DLI, donor lymphocyte infusion; EBV, Epstein-Barr virus; GVHD, graft-versus-host disease; GVL, graft-versus-lymphoma; MRD, minimal residual disease | |
| Cytoreduction for relapsed disease | Attain a state of minimal disease before SCT |
| In autologous SCT | |
| During stem cell harvest | In vivo purge |
| Maintenance after SCT | Treat MRD |
| In allogeneic SCT | |
| With conditioning regimen | Enhance GVL and tumor kill, decrease risk of GVHD |
| With DLI | Treat MRD, enhance GVL |
| Post-transplantation complications | |
| Chronic GVHD | Treat manifestations |
| EBV-associated lymphoma | Treat and prevent |